Profile data is unavailable for this security.
About the company
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
- Revenue in USD (TTM)0.00
- Net income in USD-132.35m
- Incorporated2016
- Employees85.00
- LocationCullinan Therapeutics IncOne Main Street, Suite 1350CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 410-4650
- Fax+1 (302) 655-5049
- Websitehttps://cullinantherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CareDx Inc | 275.11m | -183.19m | 808.86m | 635.00 | -- | 3.14 | -- | 2.94 | -3.43 | -3.43 | 5.16 | 4.95 | 0.5611 | 5.35 | 4.61 | 433,245.70 | -37.36 | -17.54 | -43.69 | -20.85 | 62.94 | 65.50 | -66.59 | -27.78 | 4.03 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
Relay Therapeutics Inc | 35.33m | -329.12m | 844.24m | 309.00 | -- | 1.13 | -- | 23.90 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Silence Therapeutics plc | 33.82m | -44.75m | 849.68m | 115.00 | -- | 5.27 | -- | 25.12 | -0.3932 | -0.3932 | 0.2871 | 1.14 | 0.1829 | -- | 5.37 | 294,105.80 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Rapport Therapeutics Inc | 0.00 | -51.31m | 875.27m | 58.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | 5.52 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
ARS Pharmaceuticals Inc | 10.00k | -49.70m | 881.75m | 24.00 | -- | 3.93 | -- | 88,174.68 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Pharvaris NV | 0.00 | -115.15m | 896.05m | 82.00 | -- | 2.30 | -- | -- | -2.57 | -2.57 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
Tyra Biosciences Inc | 0.00 | -75.45m | 898.43m | 49.00 | -- | 2.30 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Tango Therapeutics Inc | 37.23m | -111.65m | 914.60m | 140.00 | -- | 3.45 | -- | 24.57 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Cullinan Therapeutics Inc | 0.00 | -132.35m | 932.52m | 85.00 | -- | 1.64 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
MiMedx Group Inc | 334.51m | 71.52m | 1.00bn | 895.00 | 18.02 | 6.43 | 12.58 | 3.00 | 0.3767 | 0.3393 | 2.15 | 1.06 | 1.72 | 2.82 | 6.58 | 373,754.20 | 41.80 | -4.14 | 53.13 | -5.90 | 83.50 | 83.61 | 24.36 | -2.70 | 2.71 | 9.00 | 0.111 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.00bn | 284.00 | -- | -- | -- | 24.14 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.03bn | 267.00 | -- | -- | -- | 2.49 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Enliven Therapeutics Inc | 0.00 | -79.60m | 1.05bn | 46.00 | -- | 3.30 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Mar 2024 | 3.20m | 5.55% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 2.66m | 4.61% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.16m | 3.74% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.73m | 2.99% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.43m | 2.47% |
Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 1.35m | 2.34% |
Braidwell LPas of 31 Mar 2024 | 1.24m | 2.15% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.11m | 1.92% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.09m | 1.89% |
Adage Capital Management LPas of 31 Mar 2024 | 950.00k | 1.65% |